Piper Jaffray analyst Joseph Catanzaro conducted two key opinion leader calls to gauge sentiment around the data included in Seattle Genetics' Echelon-2 label expansion of Adcetris into CD30+ front-line T-cell lymphoma. The leaders provided "overwhelmingly positive feedback" specifically for anaplastic large cell lymphoma patients, and dismissed any concerns cited with Echelon-1, Catanzaro tells investors in a research note. The analyst, however, awaits greater clarity on the non-ALCL subgroup analyses at the upcoming American Society of Hematology meeting and reiterates a Neutral rating on Seattle Genetics with a $66 price target.